Volvo ditches diesel for its smallest SUV, but plumps up value
The XC40 T4 R Design gets more equipment, and a new petrol powertrain, in addition to a better safety kit
Drug firm Alembic Pharmaceuticals on Wednesday said it has received final nod from the US health regulator for Tizanidine hydrochloride capsules, used to treat spasticity.
“The company has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tizanidine Hydrochloride Capsules, 2 mg, 4 mg, and 6 mg,” the drug firm said in a regulatory filing.
Tizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the management of spasticity.
Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride capsules should be reserved for those daily activities and times when relief of spasticity is most important.
“The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Zanaflex Capsules, 2 mg, 4 mg, and 6 mg, of Covis Pharma BV,” the filing said.
Tizanidine hydrochloride capsules, 2 mg, 4 mg, and 6 mg have an estimated market size of USD 28 million for twelve months ending September 2019 according to IQVIA.
Alembic has a cumulative total of 111 ANDA approval – 99 final approvals and 12 tentative approvals –from USFDA.
The shares of Alembic Pharmaceuticals Ltd were trading at ₹573, up 1.96 per cent on BSE in morning trade.